Skip to main content
UniHealth

Doctor search

Jason Gotlib, MD

Hematology · Stanford

NPI 1790827640

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
18
4 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Community Hospital of the Monterey Peninsula · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

18 plans · 4 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Gotlib’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

18 of 18 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Anthem Full Dual Advantage Aligned (HMO D-SNP)Anthem Blue CrossListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

Hospitals they work in

3 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Community Hospital of the Monterey Peninsula
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.48 (1.22 to 1.74)WorseJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths3.12 (1.69 to 4.56) · 1,095 casesWorseJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths19.24 (14.17 to 24.3) · 1,118 casesWorseJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths9.62 (6.42 to 12.82) · 1,086 casesWorseJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.39BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.27 (0.39 to 2.16) · 1,873 casesNo differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths158.2 (110.65 to 205.75) · 140 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.3 · 74 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.8 · 135 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10 · 184 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.7 · 686 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths16.4 · 1,072 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8 · 328 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.8 · 3,300 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.29 (0.11 to 0.48) · 10,234 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.1 to 0.46) · 10,572 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.25 (1.47 to 5.04) · 2,617 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.37 (1.04 to 3.7) · 2,519 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths2.21 (0.75 to 3.66) · 744 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.61 (0.06 to 1.17) · 8,715 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths5.2 · 156 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.28No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.799No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.732No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.7 · 152 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.6 · 625 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits6.3 · 193 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-3.2 · 749 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits7 · 1,074 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.5 · 850 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4 (2.7 to 5.8) · 224 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits13.5 (10.4 to 17.4) · 224 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.7 · 153 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits11.5 · 49 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 144 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits14.2 (10.9 to 18.6) · 711 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.2 (1 to 1.5) · 746 casesNo differentJan 2024 – Dec 2024

What patients said (520 patients answered, 28% of those asked)

Patient survey stars by topic at Community Hospital of the Monterey Peninsula
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information3
Overall hospital rating5
Quietness3
Recommend hospital5
Share of patients giving the best answer at Community Hospital of the Monterey Peninsula
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained62%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge84%
Doctors "always" explained things so they could understand75%
Doctors "always" listened carefully79%
Doctors "always" treated them with courtesy and respect89%
Patients who gave a rating of "9" or "10" (high)82%
Staff "always" explained new medications79%
Nurses "always" explained things so they could understand79%
Nurses "always" listened carefully77%
Nurses "always" treated them with courtesy and respect89%
"Always" quiet at night54%
"YES", patients would definitely recommend the hospital84%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms88%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$74,439

Medicare paid this office $74,439 for 273 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes50$23,587$106
Return visit (30+ min)119$19,723$83
Return visit (30+ min)96$18,103$116
Initial hospital care with moderate level of medical decision making at least 75 minutes27$4,656$155
New patient visit (60+ min)26$4,153$160
See all 6 services
Every Original Medicare service billed
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes50$23,587$106
Return visit (30+ min)119$19,723$83
Return visit (30+ min)96$18,103$116
Initial hospital care with moderate level of medical decision making at least 75 minutes27$4,656$155
New patient visit (60+ min)26$4,153$160
Hospital discharge day management, 30 minutes or less21$1,772$74

Who their Medicare patients are

273 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 14% · Women 54% · Also on Medicaid 15% · Health risk score 2.05. At or below the middle of the specialty; the typical hematology clinician is at 2.35.

Conditions among them: High blood pressure 64% · Chronic kidney disease 31% · Coronary heart disease 29% · Atrial fibrillation 24% · Cancer 21% · Heart failure 19% · Diabetes 17% · COPD 14% · Depression 14% · Stroke 10% · Dementia 9%.

The office billed $293,029, Medicare allowed $96,356 and paid $74,439; for 712 services of 8 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024273712752.05$293,029$74,439
2023277738741.90$277,731$74,067
2022281804732.11$344,713$74,945
2021261796732.24$366,809$77,427
2020250829732.44$341,806$72,982
2019238681722.15$150,249$58,571
2018206680732.34$145,109$57,326
2017208728712.55$195,047$62,832
2016196664722.15$176,448$54,600
2015148455742.19$126,815$38,899
2014239761732.32$192,185$59,971
2013251834712.09$227,350$67,830

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 5 services

Original Medicare services billed in 2023
Return visit (30+ min)181$32,307$87
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes51$28,508$109
New patient visit (60+ min)36$5,678$158
Initial hospital care with moderate level of medical decision making at least 75 minutes27$4,318$160
Hospital discharge day management, 30 minutes or less28$2,225$74

2022: 5 services

Original Medicare services billed in 2022
Return visit (30+ min)191$34,662$85
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes55$26,289$92
New patient visit (60+ min)29$4,892$169
Initial hospital care with moderate level of medical decision making at least 75 minutes22$4,879$181
Hospital discharge day management, 30 minutes or less32$2,476$67

2021: 5 services

Original Medicare services billed in 2021
Return visit (30+ min)167$37,467$87
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes48$22,719$95
Initial hospital care with moderate level of medical decision making at least 75 minutes32$7,032$185
New patient visit (60+ min)35$5,852$167
Hospital discharge day management, 30 minutes or less30$2,445$68

2020: 6 services

Original Medicare services billed in 2020
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes53$28,069$97
Return visit (30+ min)145$23,316$66
Initial hospital care with moderate level of medical decision making at least 75 minutes43$8,922$190
New patient visit (60+ min)33$4,767$144
Hospital discharge day management, 30 minutes or less41$3,085$70
Return visit (30+ min)37$2,962$72

2019: 5 services

Original Medicare services billed in 2019
Return visit (30+ min)138$24,156$67
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes44$17,262$94
New patient visit (60+ min)52$7,484$144
Initial hospital care with moderate level of medical decision making at least 75 minutes33$6,607$184
Hospital discharge day management, 30 minutes or less30$2,229$66

2018: 5 services

Original Medicare services billed in 2018
Return visit (30+ min)125$25,130$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes37$17,132$94
New patient visit (60+ min)40$5,829$146
Initial hospital care with moderate level of medical decision making at least 75 minutes28$5,458$182
Hospital discharge day management, 30 minutes or less21$1,672$67

2017: 5 services

Original Medicare services billed in 2017
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes53$25,800$93
Return visit (30+ min)121$23,045$68
Initial hospital care with moderate level of medical decision making at least 75 minutes28$5,257$181
New patient visit (60+ min)35$5,118$146
Hospital discharge day management, 30 minutes or less25$1,789$66

2016: 5 services

Original Medicare services billed in 2016
Return visit (30+ min)128$25,455$68
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes32$17,774$91
New patient visit (60+ min)44$6,488$147
Initial hospital care with moderate level of medical decision making at least 75 minutes17$3,245$180
Hospital discharge day management, 30 minutes or less15$1,052$66

2015: 4 services

Original Medicare services billed in 2015
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes27$19,744$92
Return visit (30+ min)96$13,216$70
New patient visit (60+ min)11$1,653$150
Hospital discharge day management, 30 minutes or less13$841$60

2014: 5 services

Original Medicare services billed in 2014
Return visit (30+ min)157$29,900$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes37$17,114$90
New patient visit (60+ min)40$5,736$143
Initial hospital care with moderate level of medical decision making at least 75 minutes19$3,333$175
Hospital discharge day management, 30 minutes or less17$1,088$64

2013: 5 services

Original Medicare services billed in 2013
Return visit (30+ min)145$26,841$63
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes50$23,600$90
New patient visit (60+ min)56$7,460$133
Initial hospital care with moderate level of medical decision making at least 75 minutes36$6,853$176
Hospital discharge day management, 30 minutes or less27$1,856$64

Medicaid work

$3,557 in 2023

Medicaid paid $3,557 for 57 billed services this clinician did in 2023, up to 12 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2023
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES57$3,557
Medicaid work by year
202357112$3,557
202298118$4,016
202165114$4,700
See the largest Medicaid services in earlier years

2022

Largest Medicaid services in 2022
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES98$4,016

2021

Largest Medicaid services in 2021
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES65$4,700

Drugs they prescribed that Part D paid

$749,988

Pharmacies billed $749,988 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

38 generic and 42 brand-name prescriptions · $749,988 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Ayvakit15$592,340$39,489

Year by year

Part D prescribing by year
20248021None53%$749,988
202336160% (0)None$48,701
202261230% (0)43%$274,851
202192290% (0)46%$657,921
202018647None43%$793,558
2019267750% (0)43%$1,091,804
2018263610% (0)54%$1,422,005
2017289670% (0)39%$1,060,538
201621451None49%$958,550
2015246510% (0)53%$939,232
201452474None51%$2,315,588
201351976NoneNone$1,705,935

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2022: 1 drug

Part D drugs prescribed in 2022
PanzygaImmune globulin13$76,512$5,886

2021: 2 drugs

Part D drugs prescribed in 2021
Jakafi35$573,992$16,400
Allopurinol13$80$6

2020: 3 drugs

Part D drugs prescribed in 2020
Jakafi53$649,968$12,264
Acyclovir18$254$14
Sulfamethoxazole-Trimethoprim11$75$7

2019: 7 drugs

Part D drugs prescribed in 2019
Jakafi47$625,516$13,309
Procrit12$51,325$4,277
Hydroxyurea16$816$51
Allopurinol34$420$12
Valacyclovir11$303$28
Acyclovir14$133$10
Prednisone14$106$8

2018: 4 drugs

Part D drugs prescribed in 2018
Jakafi67$885,604$13,218
Hydroxyurea24$1,022$43
Allopurinol18$278$15
Acyclovir14$133$9

2017: 6 drugs

Part D drugs prescribed in 2017
Jakafi68$730,970$10,750
Revlimid12$104,342$8,695
Hydroxyurea30$1,950$65
Allopurinol27$394$15
Ondansetron13$283$22
Acyclovir15$213$14

2016: 3 drugs

Part D drugs prescribed in 2016
Jakafi80$854,886$10,686
Hydroxyurea23$744$32
Allopurinol22$233$11

2015: 6 drugs

Part D drugs prescribed in 2015
Jakafi82$790,950$9,646
Procrit12$43,216$3,601
Hydroxyurea28$1,125$40
Ondansetron17$874$51
Allopurinol21$243$12
Ranitidine13$221$17

2014: 9 drugs

Part D drugs prescribed in 2014
Jakafi141$1,502,474$10,656
Revlimid43$309,543$7,199
Exjade19$179,255$9,434
Procrit21$52,904$2,519
Hydroxyurea83$3,048$37
Anagrelide19$383$20
Allopurinol48$337$7
Ranitidine14$314$22
Prednisone15$149$10

2013: 13 drugs

Part D drugs prescribed in 2013
Jakafi116$1,037,198$8,941
Revlimid42$338,722$8,065
Exjade30$206,904$6,897
Sprycel11$48,779$4,434
Procrit13$30,205$2,323
Hydroxyurea55$2,514$46
Pantoprazole22$301$14
Anagrelide11$247$22
Allopurinol34$226$7
Acyclovir14$212$15
Ranitidine15$186$12
Gabapentin17$98$6
Dexamethasone16$85$5

Money from drug and device companies

$19,362 in 2025

Industry payments by year
202537$19,142$19,362
202426$1,999$2,285
202315$9,685$9,797
202237$7,163$7,509
202137$13,014$13,105
202013$7,855$7,855
201913$3,075$3,137

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Blueprint MedicinesNone$10,129
2 payments
  • Meals · 2025-06-14 · $130
  • Paid to speak or teach · 2025-01-02 · $9,999
IncyteNone$9,212
4 payments
  • Consulting · 2025-07-12 · $923
  • Meals · 2025-06-12 · $69
  • Consulting · 2025-01-28 · $4,110
  • Consulting · 2025-01-28 · $4,110
CelgeneReblozyl$21
1 payment
  • Meals for Reblozyl · 2025-10-02 · $21
See all 7 published payments
Every published payment
CelgeneMeals · 2025-10-02Reblozyl$21
IncyteConsulting · 2025-07-12None$923
Blueprint MedicinesMeals · 2025-06-14None$130
IncyteMeals · 2025-06-12None$69
IncyteConsulting · 2025-01-28None$4,110
IncyteConsulting · 2025-01-28None$4,110
Blueprint MedicinesPaid to speak or teach · 2025-01-02None$9,999
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $2,285

Payments by company in 2024
IncyteNone$2,215
5 payments
  • Consulting · 2024-09-30 · $1,076
  • Meals · 2024-07-12 · $60
  • Consulting · 2024-07-12 · $923
  • Meals · 2024-06-13 · $16
  • Meals · 2024-06-12 · $140
Blueprint MedicinesAyvakit$70
1 payment
  • Meals for Ayvakit · 2024-05-17 · $70

2023: $9,797

Payments by company in 2023
IncytePemazyre$9,797
5 payments
  • Meals · 2023-09-12 · $60
  • Meals · 2023-08-06 · $52
  • Consulting · 2023-06-30 · $915
  • Consulting for Pemazyre · 2023-01-23 · $7,540
  • Consulting · 2023-01-16 · $1,230

2022: $7,509

Payments by company in 2022
IncytePemazyre$5,356
2 payments
  • Consulting for Pemazyre · 2022-11-08 · $2,460
  • Paid to speak or teach · 2022-11-02 · $2,896
Blueprint MedicinesNone$1,886
4 payments
  • Honoraria · 2022-10-20 · $1,540
  • Meals · 2022-09-15 · $22
  • Meals · 2022-09-15 · $30
  • Travel · 2022-09-15 · $294
AstraZeneca Pharmaceuticals LPNone$267
1 payment
  • Paid to speak or teach · 2022-10-25 · $267

2021: $13,105

Payments by company in 2021
Blueprint MedicinesAyvakit$8,005
5 payments
  • Honoraria for Ayvakit · 2021-10-21 · $3,234
  • Honoraria · 2021-09-02 · $2,340
  • Education · 2021-08-17 · $32
  • Education · 2021-08-17 · $59
  • Honoraria · 2021-06-10 · $2,340
IncytePemazyre$3,075
1 payment
  • Consulting for Pemazyre · 2021-11-08 · $3,075
AbbVieNone$2,025
1 payment
  • Consulting · 2021-05-17 · $2,025

2020: $7,855

Payments by company in 2020
Blueprint MedicinesAyvakit$7,855
3 payments
  • Honoraria · 2020-06-24 · $3,510
  • Honoraria for Ayvakit · 2020-05-12 · $4,095
  • Consulting for Ayvakit · 2020-04-21 · $250

2019: $3,137

Payments by company in 2019
IncyteNone$3,137
3 payments
  • Consulting · 2019-11-26 · $3,075
  • Meals · 2019-10-25 · $39
  • Meals · 2019-10-25 · $22

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Blueprint Medicines Corporation · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2021Their institution$779,811
Blueprint Medicines Corporation · An Open-Label, Single Arm, Phase 2 Study To Evaluate Efficacy and Safety of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · 2020Their institution$618,728
Blueprint Medicines Corporation · An Open-Label, Single Arm, Phase 2 Study To Evaluate Efficacy and Safety of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · 2021Their institution$591,278
Blueprint Medicines Corporation · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2020Their institution$525,788
Incyte Corporation · A Study To Evaluate the Safety, Tolerability of Incb160058 in Participants With Myeloproliferative Neoplasms · 2025Their institution$447,905
Blueprint Medicines Corporation · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2022Their institution$408,660
Blueprint Medicines Corporation · 2020Their institution$366,018
Blueprint Medicines Corporation · (Explorer) Study of Blu-285 in Patients With Advanced Systemic Mastocytosis (Advsm) and Relapsed Or Refractory Myeloid Malignancies · 2021Their institution$320,851
Incyte Corporation · A Phase 1/2, Open Label, Dose Escalation, Safety and Tolerability Study of Incagn01876 in Subjects With Advanced Or Metastatic Solid Tumors · 2020Their institution$315,633
Blueprint Medicines Corporation · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2023Their institution$303,403
Blueprint Medicines Corporation · An Open-Label, Single Arm, Phase 2 Study To Evaluate Efficacy and Safety of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · 2022Their institution$285,852
Blueprint Medicines Corporation · 2022-Rfp-002: Characterizing the Cellular Dynamics of Kit D816v Mutated Systemic Mastocytosis on Avapritinib and Blu-263 · 2024Their institution$193,230
Incyte Corporation · A Phase 1, Open-Label, Multicenter Study of Incb161734 in Participants With Advanced Or Metastatic Solid Tumors With Kras G12d Mutation · 2024Their institution$191,967
Celgene Corporation · A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With Or Without Red Blood Cell-Transfusion Dependence (Ace-536-Mf-001) · 2019Their institution$146,545
Blueprint Medicines Corporation · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2024Their institution$145,304
Blueprint Medicines Corporation · An Open-Label, Single Arm, Phase 2 Study To Evaluate Efficacy and Safety of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · 2023Their institution$142,488
Blueprint Medicines Corporation · (Explorer) Study of Blu-285 in Patients With Advanced Systemic Mastocytosis (Advsm) and Relapsed Or Refractory Myeloid Malignancies · 2022Their institution$116,624
Blueprint Medicines Corporation · 2022-Rfp-002: Characterizing the Cellular Dynamics of Kit D816v Mutated Systemic Mastocytosis on Avapritinib and Blu-263 · 2023Their institution$115,937
Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2021Their institution$111,441
Blueprint Medicines Corporation · An Open-Label, Single Arm, Phase 2 Study To Evaluate Efficacy and Safety of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · 2024Their institution$101,355
Acerta Pharma LLC · A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acp-196 in Combination With Obinutuzumab, and Acp-196 Monotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia · 2022Their institution$97,928
Blueprint Medicines Corporation · Blu-285-2202 / Blu-285-2203 / Blu-263-1201 · 2022Their institution$96,000
Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2022Their institution$94,655
Incyte Corporation · A Phase 1/2 Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy Or in Combination With Ruxolitinib in Participants With Anemia Due To Myeloproliferative Disorders · 2024Their institution$86,008
Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2023Their institution$81,874
Blueprint Medicines Corporation · An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis · 2021Their institution$80,750
Blueprint Medicines Corporation · (Explorer) Study of Blu-285 in Patients With Advanced Systemic Mastocytosis (Advsm) and Relapsed Or Refractory Myeloid Malignancies · 2023Their institution$80,219
Acerta Pharma LLC · A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acp-196 in Combination With Obinutuzumab, and Acp-196 Monotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia · 2023Their institution$74,904
Incyte Corporation · A Phase 1/2 Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy Or in Combination With Ruxolitinib in Participants With Anemia Due To Myeloproliferative Disorders · 2023Their institution$72,102
SANOFI US SERVICES INC. · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2025Their institution$70,975
Blueprint Medicines Corporation · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2025Their institution$69,980
Incyte Corporation · A Phase 1/2 Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy Or in Combination With Ruxolitinib in Participants With Anemia Due To Myeloproliferative Disorders · 2022Their institution$65,423
Blueprint Medicines Corporation · An Open-Label, Single Arm, Phase 2 Study To Evaluate Efficacy and Safety of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · 2025Their institution$63,617
Incyte Corporation · This Study Is Being Conducted To Assess the Safety, Tolerability, and Pharmacokinetics of Incb160058 in Participants With Myeloproliferative Neoplasms. · 2025Their institution$62,214
Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2025Their institution$59,059
Acerta Pharma LLC · A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acp-196 in Combination With Obinutuzumab, and Acp-196 Monotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia · 2024Their institution$58,000
Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2021Their institution$44,285
Incyte Corporation · A Phase 1/2 Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy Or in Combination With Ruxolitinib in Participants With Anemia Due To Myeloproliferative Disorders · 2025Their institution$42,890
Seattle Genetics, Inc. · A Pilot Study of Brentuximab Vedotin Sgn-35 in Cd30-Positive Systemic Mastocytosis With Or Without An Associated Hematological Clonal Non-Mast Cell Lineage Disease Ahnmd · 2019Their institution$42,116
Incyte Corporation · Ruxolitinib in Primary Eosinophilic Disorders and Idiopathic Hypereosinophilic Syndrome · 2020Their institution$41,015
SANOFI US SERVICES INC. · A Phase 1/2, Open-Label, 2-Arm Study Evaluating Blu-263 As Monotherapy and in Combination With Azacitidine, in Patients With Kit Altered Hematologic Malignancies · 2025Their institution$38,464
Acerta Pharma LLC · A Randomized,Multicenter,Open Label,3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil,Acp 196 in Combination With Obinutuzumaband Acp 196 Monotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia · 2025Their institution$38,185
Incyte Corporation · This Phase 1/2, Open-Label, Dose-Finding Study Is Intended To Evaluate the Safety and Tolerability, Pk, Pd, and Efficacy of Incb000928 Administered As Monotherapy Or in Combination With Ruxolitinib in Participants With Mf Who Are Transfusion-Dependent Or Presenting With Symptomatic Anemia. This Study Will Consist of 2 Parts: Dose Escalation and Expansion. · 2025Their institution$36,686
Celgene Corporation · A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With Or Without Red Blood Cell-Transfusion Dependence · 2020Their institution$36,036
Incyte Corporation · A Phase 1/2 Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy Or in Combination With Ruxolitinib in Participants With Anemia Due To Myeloproliferative Disorders · 2021Their institution$33,979
Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2024Their institution$33,776
Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Active-Controlled Study Evaluating Momelotinib Vs. Ruxolitinib in Subjects With Primary Myelofibrosis (Pmf) Or Post-Polycythemia Vera Or Post- Essential Thrombocythemia Myelofibrosis (Post-Pv/Et Mf) · 2019Their institution$23,548
Gilead Sciences, Inc. · Open-Label Study To Assess the Long-Term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera Or Essential Thrombocythemia · 2019Their institution$23,390
Pharmacyclics LLC, an AbbVie Company · Extended Treatment Protocol for Subjects Continuing To Benefit From Ibrutinib. · 2023Their institution$21,371
Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Active-Controlled Study Evaluating Momelotinib Vs. Ruxolitinib in Subjects With Primary Myelofibrosis (Pmf) Or Post-Polycythemia Vera Or Post- Essential Thrombocythemia Myelofibrosis (Post-Pv/Et Mf) · 2020Their institution$21,246
ABBVIE INC. · A Phase 2 Open-Label Study of the Efficacy and Safety of Abt-199 (Gdc-0199) in Chronic Lymphocytic Leukemia (Cll) Subjects With Relapse Or Refractory To B-Cell Receptor Signaling Pathway Inhibitor Therapy · 2022Their institution$20,992
Pharmacyclics LLC, an AbbVie Company · Extended Treatment Protocol for Subjects Continuing To Benefit From Ibrutinib. · 2022Their institution$15,518
Gilead Sciences, Inc. · Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (Pmf) Or Post-Polycythemia Vera Or Post-Essential Thrombocythemia Myelofibrosis (Post-Pv/Et Mf) · 2019Their institution$13,144
Blueprint Medicines Corporation · An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis · 2022Their institution$11,888
ABBVIE INC. · Extended Treatment Protocol for Subjects Continuing To Benefit From Ibrutinib. · 2024Their institution$10,700
Incyte Corporation · A Phase 2, Open Label, Single Arm, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Advanced/Metastatic Or Surgically Unresectable Cholangiocarcinoma Including Fgfr2 Translocations Who Failed Previous Therapy · 2020Their institution$10,560
ABBVIE INC. · A Phase 2 Open-Label Study of the Efficacy and Safety of Abt-199 (Gdc-0199) in Chronic Lymphocytic Leukemia (Cll) Subjects With Relapse Or Refractory To B-Cell Receptor Signaling Pathway Inhibitor Therapy · 2023Their institution$8,909
Incyte Corporation · Prospective, Longitudinal, Non Interventional Study of Disease Burden and Treatment of Patients With Low Risk Myelofibrosis Mf Or High Risk Essential Thrombocythemia Et Or Et Patients Receiving Et Directed Therapy · 2019Their institution$8,144
ABBVIE INC. · Extended Treatment Protocol for Subjects Continuing To Benefit From Ibrutinib. · 2025Their institution$7,613
Celgene Corporation · A Phase-2 Study To Determine Efficacy and Safety O - A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With Or Without Red Blood Cell-Transfusion Dependence · 2022Their institution$6,805
Celgene Corporation · A Phase-2 Study To Determine Efficacy and Safety O · 2021Their institution$6,215
F. Hoffmann-La Roche AG · Safety and Efficacy of Zinpentraxin Alfa As Monotherapy Or in Combination With Ruxolitinib in Myelofibrosis: Stage 1 of A Phase II Trial · 2023This clinician$4,557
Novartis Pharmaceuticals Corporation · Research Related Publications Support · 2020This clinician$3,750
Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloidlymphoid Neoplasms With Fgfr1 Rearrangement · 2019Their institution$3,226
Blueprint Medicines Corporation · An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis · 2023Their institution$2,240
Blueprint Medicines Corporation · An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis · 2024Their institution$2,240
Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2022Their institution$1,728
Incyte Corporation · A Phase 1/2 Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy Or in Combination With Ruxolitinib in Participants With Anemia Due To Myeloproliferative Disorders · 2020Their institution$1,611
Incyte Corporation · Ruxolitinib in Primary Eosinophilic Disorders and Idiopathic Hypereosinophilic Syndrome · 2022Their institution$1,250
Novartis Pharmaceuticals Corporation · A Single Arm Phase II Open Label Study To Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered To Patients With Aggressive Systemic Mastocytosis Or Mast Cell Leukemia Plus Or Minus An Associated Hematological Clonal Non Mast · 2019Their institution$1,178
Celgene Corporation · A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With Or Without Red Blood Cell-Transfusion Dependence (Ace-536-Mf-001) · 2019This clinician$935
Acerta Pharma LLC · A Randomized,Multicenter,Open Label,3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil,Acp 196 in Combination With Obinutuzumaband Acp 196 Monotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia · 2024Their institution$448
Gilead Sciences, Inc. · A Phase 1b Open-Label Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Subjects Receiving Ruxolitinib As Therapy for Primary, Post-Polycythemia Vera, Or Post-Essential Thrombocythemia Myelofibrosis With Progressive Or Relapsed Disease · 2020Their institution$391
Incyte Corporation · A Phase 1, Open-Label, Multicenter Study of Inca033989 in Participants With Myeloproliferative Neoplasms · 2023Their institution$107

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1790827640
Licence
CA A060833
Trained
Stanford University School of Medicine, 1995
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RH0000X (207RH0000X)
Mailing address
875 Blake Wilbur Drive, Room 2327b, Stanford, CA, 94305
NPI first listed
2007-02-13
NPI last updated
2007-07-08

This is when the NPI record was last certified, not a medical board exam.